As part of its advocacy program in Europe, ACRO submits regulatory comments to European officials. This comment letter, submitted by ACRO to the European Commission on November 7, 2025, regarding the public questionnaire informing the European Biotech Act can be found below. ACRO offers 10 recommendations for inclusion in the EU Biotech Act to help achieve these goals and strengthen the EU’s competitiveness and attractiveness for global clinical trial placement.